In a significant stride towards unraveling the mysteries of Alzheimer’s disease, several members of the AMYPAD project travelled to Boston for the 16th edition of the Clinical Trials on Alzheimer’s Disease (CTAD) conference held from October 24 to 27, 2023.

CTAD is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer’s disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease.

Dr. Juan Domingo Gispert, head of the Neuroimaging Research Group at the Barcelonaβeta Brain Research Center (BBRC) presented two scientific posters and an oral talk.

• “Stress testing the centiloid concept: validation of the between-tracer accuracy of the centiloid method in an independent cohort” (P059): This study included 158 participants of the EPAD Longitudinal Cohort Study (LCS) and the AMYPAD Prognostic and Natural History Study (PNHS) who underwent amyloid PET scanning.
• “Stress testing the CL concept:validation of generalizable centiloid cut-off values in two large, independent and representative clinical alzheimer cohorts” (LP040): This work included 984 amyloid PET scans from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) project and 729 scans from the AMYPAD Diagnostic and Patient Management Study (DPMS).
• Stress Testing the Centiloid concept: Evaluating Centiloid Stability to Tracer, Effective Image Resolution and Quantification Method” (OC15): A total of 533 participants from AMYPAD DPMS and ADNI  who were cognitively unimpaired (CU) or had subjective memory complaints (SMC), mild cognitive impairment (MCI), or dementia were included in this work. Juan Domingo presented this talk on behalf of M. Shekari.

Mark the dates! The 17th annual CTAD conference will be held in Madrid (Spain) on October 29 – November 1, 2024!